Tag Archives: anti-inflammatory

How A Kidney Drug Almost Torpedoed Concert Pharma’s IPO

[Updated, 4/27/14, 10:49 am ET] Drug development is a humbling thing. Hard as you might try, the numbers show that 90 percent of the time, you’ll fail. What if the signs of such a failure were to emerge, of all times, when you’re pitching an IPO? That’s just the situation that Concert Pharmaceuticals confronted last […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, Raleigh-Durham blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

San Diego Life Sciences Roundup: Arena, Organovo, Isis, & More

[Corrected 6/15/13, 11:45 pm. See below.] It seemed to be a week of positive news for San Diego’s life sciences community. We have the details wrapped up here. —CalBio 2013 convened at the San Diego Convention Center yesterday with an opening keynote talk by J. Craig Venter, the human genome pioneer and founding CEO of […]

Posted in National blog main, San Diego, San Diego blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on San Diego Life Sciences Roundup: Arena, Organovo, Isis, & More

Momenta, Baxter Team Up on Biosimilars

Illinois-based Baxter International (NYSE: BAX) is tapping into Cambridge, MA-based Momenta Pharmaceuticals’ abilities as a generic drugmaker in a new collaboration deal focused on developing so-called biosimilars, or knockoffs of biologic drugs. Momenta (NASDAQ: MNTA) will receive $33 million upfront in the deal, according to an announcement yesterday, and could receive another $419 million in potential milestones […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , , , | 1 Comment